Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1977 1
1978 3
1979 1
1980 6
1981 5
1982 10
1983 15
1984 9
1985 21
1986 19
1987 33
1988 23
1989 31
1990 33
1991 43
1992 26
1993 20
1994 28
1995 38
1996 38
1997 32
1998 54
1999 56
2000 54
2001 57
2002 40
2003 52
2004 60
2005 79
2006 73
2007 69
2008 93
2009 92
2010 116
2011 135
2012 118
2013 139
2014 140
2015 150
2016 104
2017 99
2018 159
2019 172
2020 191
2021 201
2022 169
2023 132
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

2,951 results

Results by year

Filters applied: . Clear all
Page 1
Magnesium sensing via LFA-1 regulates CD8(+) T cell effector function.
Lötscher J, Martí I Líndez AA, Kirchhammer N, Cribioli E, Giordano Attianese GMP, Trefny MP, Lenz M, Rothschild SI, Strati P, Künzli M, Lotter C, Schenk SH, Dehio P, Löliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grählert J, Kuzmin D, Burgener AV, Merkler D, Pless M, Balmer ML, Reith W, Huwyler J, Irving M, King CG, Zippelius A, Hess C. Lötscher J, et al. Among authors: lenz m. Cell. 2022 Feb 17;185(4):585-602.e29. doi: 10.1016/j.cell.2021.12.039. Epub 2022 Jan 19. Cell. 2022. PMID: 35051368 Free article.
Here, we show that the co-stimulatory cell-surface molecule LFA-1 requires magnesium to adopt its active conformation on CD8(+) T cells, thereby augmenting calcium flux, signal transduction, metabolic reprogramming, immune synapse formation, and, as a consequence, specific …
Here, we show that the co-stimulatory cell-surface molecule LFA-1 requires magnesium to adopt its active conformation on CD8(+) T cel …
Enhancer viruses for combinatorial cell-subclass-specific labeling.
Graybuck LT, Daigle TL, Sedeño-Cortés AE, Walker M, Kalmbach B, Lenz GH, Morin E, Nguyen TN, Garren E, Bendrick JL, Kim TK, Zhou T, Mortrud M, Yao S, Siverts LA, Larsen R, Gore BB, Szelenyi ER, Trader C, Balaram P, van Velthoven CTJ, Chiang M, Mich JK, Dee N, Goldy J, Cetin AH, Smith K, Way SW, Esposito L, Yao Z, Gradinaru V, Sunkin SM, Lein E, Levi BP, Ting JT, Zeng H, Tasic B. Graybuck LT, et al. Among authors: lenz gh. Neuron. 2021 May 5;109(9):1449-1464.e13. doi: 10.1016/j.neuron.2021.03.011. Epub 2021 Mar 30. Neuron. 2021. PMID: 33789083 Free PMC article.
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.
Heming M, Haessner S, Wolbert J, Lu IN, Li X, Brokinkel B, Müther M, Holling M, Stummer W, Thomas C, Schulte-Mecklenbeck A, de Faria F, Stoeckius M, Hailfinger S, Lenz G, Kerl K, Wiendl H, Meyer Zu Hörste G, Grauer OM. Heming M, et al. Among authors: lenz g. Genome Med. 2022 Sep 24;14(1):109. doi: 10.1186/s13073-022-01110-1. Genome Med. 2022. PMID: 36153593 Free PMC article.
Hyperexpanded B cell clones were shared between biopsy- and CSF- but not blood-derived cells. T cells in the tumor microenvironment upregulated immune checkpoint molecules, thereby recognizing immune evasion signals from PCNSL cells. ...CONCLUSIONS: Malignant B cells in PC …
Hyperexpanded B cell clones were shared between biopsy- and CSF- but not blood-derived cells. T cells in the tumor microenvironment u …
B cell and B cell-related pathways for novel cancer treatments.
Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ. Tokunaga R, et al. Among authors: lenz hj. Cancer Treat Rev. 2019 Feb;73:10-19. doi: 10.1016/j.ctrv.2018.12.001. Epub 2018 Dec 3. Cancer Treat Rev. 2019. PMID: 30551036 Free PMC article. Review.
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-en …
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoti …
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
Frontzek F, Karsten I, Schmitz N, Lenz G. Frontzek F, et al. Among authors: lenz g. Ther Adv Hematol. 2022 Jun 28;13:20406207221103321. doi: 10.1177/20406207221103321. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785244 Free PMC article. Review.
It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora …
It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace …
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Among authors: lenz g. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-r …
In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination …
Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana.
Theologis A, Ecker JR, Palm CJ, Federspiel NA, Kaul S, White O, Alonso J, Altafi H, Araujo R, Bowman CL, Brooks SY, Buehler E, Chan A, Chao Q, Chen H, Cheuk RF, Chin CW, Chung MK, Conn L, Conway AB, Conway AR, Creasy TH, Dewar K, Dunn P, Etgu P, Feldblyum TV, Feng J, Fong B, Fujii CY, Gill JE, Goldsmith AD, Haas B, Hansen NF, Hughes B, Huizar L, Hunter JL, Jenkins J, Johnson-Hopson C, Khan S, Khaykin E, Kim CJ, Koo HL, Kremenetskaia I, Kurtz DB, Kwan A, Lam B, Langin-Hooper S, Lee A, Lee JM, Lenz CA, Li JH, Li Y, Lin X, Liu SX, Liu ZA, Luros JS, Maiti R, Marziali A, Militscher J, Miranda M, Nguyen M, Nierman WC, Osborne BI, Pai G, Peterson J, Pham PK, Rizzo M, Rooney T, Rowley D, Sakano H, Salzberg SL, Schwartz JR, Shinn P, Southwick AM, Sun H, Tallon LJ, Tambunga G, Toriumi MJ, Town CD, Utterback T, Van Aken S, Vaysberg M, Vysotskaia VS, Walker M, Wu D, Yu G, Fraser CM, Venter JC, Davis RW. Theologis A, et al. Among authors: lenz ca. Nature. 2000 Dec 14;408(6814):816-20. doi: 10.1038/35048500. Nature. 2000. PMID: 11130712
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Among authors: lenz o. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
Patients were randomly assigned (1:1:2:2:2:2) via permuted block randomisation according to a computer-generated schedule to receive oral nucleos(t)ide analogues once per day plus placebo (control group); oral JNJ-6379 250 mg daily plus nucleos(t)ide analogues (JNJ- …
Patients were randomly assigned (1:1:2:2:2:2) via permuted block randomisation according to a computer-generated schedule to receive oral nu …
Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.
Schmitz N, Lenz G, Stelljes M. Schmitz N, et al. Among authors: lenz g. Blood. 2018 Jul 19;132(3):245-253. doi: 10.1182/blood-2018-01-791335. Epub 2018 Apr 26. Blood. 2018. PMID: 29699989 Free article. Review.
Mature T- and natural killer (NK)-cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common …
Mature T- and natural killer (NK)-cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinical …
Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.
Avanes A, Lenz G, Momand J. Avanes A, et al. Among authors: lenz g. Biochem Pharmacol. 2019 Feb;160:71-79. doi: 10.1016/j.bcp.2018.12.008. Epub 2018 Dec 12. Biochem Pharmacol. 2019. PMID: 30552871 Free PMC article. Review.
In 2002, the second protein product of PPP1R1B was discovered in gastric cancers: t-Darpp (truncated Darpp-32). The start codon of t-Darpp is amino acid residue 37 of Darpp-32 and it lacks the domain responsible for modulating Protein Phosphatase 1. Aside from gastr …
In 2002, the second protein product of PPP1R1B was discovered in gastric cancers: t-Darpp (truncated Darpp-32). The start codon of …
2,951 results